66 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
9 Aug 21
Business Highlights and Anticipated Second Half 2021 Milestones
7:01am
interactions and registration strategy as well as enable the identification of the broadest patient population that may benefit from STRO‑002.
STRO-001, CD74 … to strengthen leadership through the addition of a Chief Commercial Officer, promotion of a Chief Portfolio Strategy & Alliance Officer, and additions
8-K
EX-99.1
STRO
Sutro Biopharma Inc
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
strategy.
oBased on an exploratory cut-off of TPS 25%, a 40% ORR (10 PRs out of 25 patients) was observed. TPS ≤ 25% demonstrates 13% ORR.
Based … the STRO-002 dose-expansion cohort are expected to provide further information to inform regulatory discussions and a global registration strategy
8-K
EX-99.1
STRO
Sutro Biopharma Inc
16 Jun 22
Other Events
7:00am
Two-part design to explore safety, anti-tumor activity, dosing, and FolRα enrichment strategy STRO 002 Protocol Baseline Characteristics Inclusive … neutropenia Most Common G3+ TEAEs (≥2 Subjects) by Dose
Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy Emerging data inform
8-K
EX-99.1
STRO
Sutro Biopharma Inc
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
assay to determine if a FolRα-selection enrichment strategy is needed," said Bill Newell, Chief Executive Officer of Sutro Biopharma. "Additional data … from the dose-expansion will inform regulatory discussions, accelerate registration strategy, and identify the broadest population that may benefit
8-K
STRO
Sutro Biopharma Inc
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
strategy. Based on an exploratory cut-off of TPS 25%, a 40% ORR (10 PRs out of 25 patients) was observed. TPS <=25% demonstrates 13% ORR. Based … registration strategy.
This current report contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private
8-K
EX-99.1
srwe5qz8pen
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
rsw3to7iwbljx
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.2
l84cv
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
uj639bmq4 rjqs
28 Feb 22
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
4:36pm
8-K
EX-99.2
mjiemeniy yh3l2sr
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.2
8db22lcj4tk
19 May 21
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
nkwtlrfy0l5 ua0
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
PRE 14A
og3jlqmxolde5f7lsaz
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
moolz0z
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.1
lzuxbgh4
8 Jan 24
Results of Operations and Financial Condition
7:31am